TGFB1 and neoplasm: Upon binding with its ligand TGF-β, TGFBR2 is phosphorylated at the serine and threonine residues within its GS box, which could activate the TGF-β signaling pathway and lead to acquisition of resistance to the anti-mitogenic effects of TGF-β and contribute to tumor development and progression [30,31].